Targeting of IGF1R signaling using pharmacological inhibitors (NT157/OSI-906), neutralizing antibodies, or Sorafenib induces anti-proliferative effects on ALL [317], AML [114], and CLL [113] cells in vitro, respectively. This evidence concerns the gene IGF1R and B-cell chronic lymphocytic leukemia.